Abera Bioscience AB (XSAT:ABERA) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Abera Bioscience AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Abera Bioscience AB's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Abera Bioscience AB could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Abera Bioscience AB's Cash-to-Debt or its related term are showing as below:

XSAT:ABERA' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 6 years, Abera Bioscience AB's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

XSAT:ABERA's Cash-to-Debt is ranked better than
99.8% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs XSAT:ABERA: No Debt

Abera Bioscience AB Cash-to-Debt Historical Data

The historical data trend for Abera Bioscience AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Abera Bioscience AB Cash-to-Debt Chart

Abera Bioscience AB Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Abera Bioscience AB Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial														No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Abera Bioscience AB's Cash-to-Debt

For the Biotechnology subindustry, Abera Bioscience AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abera Bioscience AB's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abera Bioscience AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Abera Bioscience AB's Cash-to-Debt falls into.

Abera Bioscience AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Abera Bioscience AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Abera Bioscience AB had no debt ⁽¹⁾.

Abera Bioscience AB's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Abera Bioscience AB had no debt ⁽¹⁾.

Abera Bioscience AB (XSAT:ABERA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Abera Bioscience AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Abera Bioscience AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Abera Bioscience AB (XSAT:ABERA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abera Bioscience AB (XSAT:ABERA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Svetsarvagen 15, Solna, SWE, SE-17141

Website

https://www.aberabio.com

Abera Bioscience AB is a platform and vaccine development company based on research in the medical, molecular, and microbiological fields. The company's mission is to develop vaccine candidates based on its novel vaccine delivery platform to late pre-clinical or early clinical phase.

Abera Bioscience AB (XSAT:ABERA) Headlines

No Headlines

Abera Bioscience AB (XSAT:ABERA) Cash-to-Debt : No Debt (1) (As of Mar. 2024)